{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Methetoin, a neuropsychiatric agent possesses anticonvulsive properties. Information about the current use of this compound is not available.
Status:
Investigational
Source:
NCT00842335: Phase 1/Phase 2 Interventional Completed Advanced Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
CGI-1842 (also known as JI-101) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 that has been used in trials studying the treatment of Cancer, Colon Cancer, Neuroendocrine, Ovarian Cancer, and Advanced Solid Tumors. By targeting multiple angiogenesis signaling pathways in tumor vessel beds, CGI-1842 has the potential to inhibit multiple stages of tumor angiogenesis and thus enhance anti-tumor efficacy. In preclinical models, CGI-1842 induced concentration-dependent blocking of both EphB4- and VEGF-stimulated signaling pathways and has shown excellent antitumor activity. CGI-1842 is well tolerated in cancer patients and has shown impressive activity in Phase I clinical trials.
Class (Stereo):
CHEMICAL (RACEMIC)
Palonidipine (also known as TC 81) a calcium antagonist that was developed by Teijin for the treatment of hypertension and angina pectoris. Palonidipine was involved in phase II clinical trials in Japan. However, these studies were discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Pranidipine is the calcium channel blocker. Pranidipine did not affect the sensitivity of the contractile proteins to calcium. Pranidipine also did not alter cyclic GMP-induced relaxation in alpha-toxin-skinned vascular preparations. Pranidipine also prolonged glyceryl trinitrate-induced relaxation in the endothelium denuded rat aorta. Pranidipine enhances cyclic GMP-independent NO-induced relaxation of smooth muscle by a mechanism other than through NO-induced hyperpolarization. These effects were in direct contrast to amlodipine, another new 1,4-dihydropyridine calcium antagonist. Pranidipine increased blood velocity and probably blood flow in the optic nerve head, choroid, and retina of rabbits. Pranidipine was not detrimental to global cardiac function in animals with dilated cardiomyopathy. Pranidipine enhances relaxation produced by endothelium-derived relaxing factor in carotid artery. Pranidipine was investigated as pharmacological agent for the treatment of angina pectoris and hypertension.
Class (Stereo):
CHEMICAL (RACEMIC)
Guaimesal was studied for the treatment of exacerbated chronic bronchitis
Class (Stereo):
CHEMICAL (MIXED)
Nileprost is a prostacyclin analogue stabilized by introduction of the cyano group at its 5-position. Nileprost is a mixed type PGI2/PGE2 agonist. The development of the prostaglandin analogue nileprost [ZK 34798] for use in peptic ulcers has been discontinued at phase II by Schering AG in Germany.
Class (Stereo):
CHEMICAL (UNKNOWN)
Targets:
Igmesine is a sigma-1 receptor agonist. It was assayed in clinical trials targeting major depressive disorder. Igmesine is the only antisecretory agent that we have tested to date that inhibits both cholera toxin and the E. coli enterotoxins. Sigma receptors are known to be present on nerves in the enteric nervous system and this would seem to be a potentially useful class of drugs to pursue for the treatment of secretory diarrhoea in humans. It was shown that when Alzheimer's disease rats were submitted to the conditioned fear stress test, igmesine can significantly reduce the stress-induced motor suppression, indicating exogenous σ-1 receptor agonists may alleviate Alzheimer's disease-associated depressive symptoms.
Class (Stereo):
CHEMICAL (RACEMIC)
Furaprofen (also known as R-803), a nonsteroidal drug possesses anti-inflammatory properties. This drug was studied for the treatment of rheumatoid arthritis. However, information about the further development of this drug is not available.
Status:
Investigational
Source:
NCT01492907: Phase 1 Interventional Completed Pancreatic Cancer
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01063920: Phase 2/Phase 3 Interventional Completed Osteoarthritis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of the non-steroidal anti-inflammatory drug (NSAID) naproxen that is hydrolysed to pharmacologically active naproxen once absorbed. Naproxen etemesil was in development with Logical Therapeutics for the treatment of osteoarthritis. However, no recent development has been reported. It is also in phase I clinical trials for the treatment of inflammation and arthritis.The compound was originally developed by Medinox, licensed to Logical Therapeutics in 2006 for partial rights.
